Skip to Content


Hemostatic Medical Devices for Trauma Use; Public Workshop; Request for Comments

Document Details

Information about this document as published in the Federal Register.

Enhanced Content

Relevant information about this document from provides additional context. This information is not part of the official Federal Register document.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.


Notice of public workshop; request for comments.

The Food and Drug Administration (FDA) is announcing the following public workshop entitled “Hemostatic Medical Devices for Trauma Use.” FDA is holding this public workshop to obtain information on the current challenges and opportunities related to hemostatic medical devices for use in emergency situations. The goals of the workshop are to discuss factors that contribute to hemostatic medical device performance and reliability and types of studies used to assess bleeding and validate methods to evaluate the severity of bleeding, and to define regulatory pathways for novel products.

Dates and Times: The public workshop will be held on September 3 and 4, 2014, from 8 a.m. to 5 p.m.

Location: The public workshop will be held at FDA's White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503A), Silver Spring, MD 20993. Entrance for the public meeting participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to​AboutFDA/​WorkingatFDA/​BuildingsandFacilities/​WhiteOakCampusInformation/​ucm241740.htm.

Contact Person: Allison Kumar, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5402, Silver Spring, MD 20993, 301-796-6369,

Registration: Registration is free and available on a first-come, first-served basis. Persons interested in attending this public workshop must register online by August 22, 2014, at 4 p.m. Early registration is recommended because facilities are limited and, therefore, FDA may limit the number of participants from each organization. If time and space permits, onsite registration on the day of the meeting/public workshop will be provided beginning at 7 a.m.Start Printed Page 27876

If you need special accommodations due to a disability, please contact Susan Monahan, (email: or phone: 301-796-5661) no later than August 20, 2014.

To register for the public workshop, please visit FDA's Medical Devices News & Events—Workshops & Conferences calendar at​MedicalDevices/​NewsEvents/​WorkshopsConferences/​default.htm. (Select this meeting/public workshop from the posted events list.) Please provide complete contact information for each attendee, including name, title, affiliation, email, and telephone number. Those without Internet access should contact Allison Kumar to register (see Contact Person). Registrants will receive confirmation after they have been accepted. You will be notified if you are on a waiting list.

Streaming Webcast of the Public Workshop: This public workshop will also be Webcast. Persons interested in viewing the Webcast must register online by Wednesday, August 22, 2014. Early registration is recommended because Webcast connections are limited. Organizations are requested to register all participants, but to view using one connection per location. Webcast participants will be sent technical system requirements after registration and will be sent connection access information after August 26, 2014. If you have never attended a Connect Pro event before, test your connection at​common/​help/​en/​support/​meeting_​test.htm. To get a quick overview of the Connect Pro program, visit​go/​connectpro_​overview. (FDA has verified the Web site addresses in this document, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.)

Requests for Protocols: In advance of the public workshop, CDRH would like to invite interested stakeholders to submit protocols that describe procedures to evaluate issues (e.g., design, validation, conduct, and analysis) related to the adequacy of studies pertaining to bench testing, animal testing, bleeding severity, human factors, and clinical data collection for hemostatic products. Of particular interest to the Agency are methods for assessing high-risk products used in non-compressible wound hemorrhage.

The intention of collecting these protocols is for the Agency to review the submissions and determine viable solutions and paradigms for assessing the safety and effectiveness of hemostatic devices based on scientifically supported expert stakeholder opinions. The result of such a review will be incorporated into the public workshop for in-depth discussion and consensus potentially leading to guidance from the Agency. Please note that while FDA safeguards study protocols and all proprietary information it receives, the protocols submitted in response to this request for protocols will be shared and potentially discussed publically. The deadline for submitting protocols for this public workshop is June 27, 2014. See the comments section for information on how to submit protocols. Please note that information submitted to the docket will be publically available.

Comments: FDA is holding this public workshop to obtain information on the current challenges and opportunities related to hemostatic medical devices for use in emergency situations. In order to permit the widest possible opportunity to obtain public comment, FDA is soliciting either electronic or written comments on all aspects of the public workshop topics. The deadline for submitting comments related to this public workshop is October 3, 2014.

Regardless of attendance at the public workshop, interested persons may submit either electronic comments regarding this document to or written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. In addition, when responding to specific questions as outlined in section II of this document, please identify the question you are addressing. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at

Transcripts: Please be advised that as soon as a transcript is available, it will be accessible at It may be viewed at the Division of Dockets Management (see Comments). A transcript will also be available in either hardcopy or on CD-ROM, after submission of a Freedom of Information request. Written requests are to be sent to the Division of Freedom of Information (ELEM-1029), Food and Drug Administration, 12420 Parklawn Dr., Element Bldg., Rockville, MD 20857. A link to the transcripts will also be available approximately 45 days after the public workshop on the Internet at​MedicalDevices/​NewsEvents/​WorkshopsConferences/​default.htm. (Select this public workshop from the posted events list).

End Preamble Start Supplemental Information


I. Background

There exists a large variety of hemostatic products on the market and in development that are being used for or are intended to be used to control potentially life-threatening bleeding in emergency situations when there may be no immediate medical facility nearby. Such devices may fit into various medical device regulatory categories such as the absorbable hemostatic agents (21 CFR 878.4490), externally applied vascular clamps (21 CFR 870.4450), various other class II devices, unclassified products (proposed for classification into class II), and those that may be proposed for other regulatory pathways, such as de novo petitions or PMA applications. There are currently a number of scientific and clinical challenges faced by industry and FDA that hamper the evaluation of such products. These include: The difficulty in measuring severity of bleeding in a consistent, reproducible and/or standardized manner, the lack of a bleeding severity scale (i.e., operationalizing the definition of bleeding severity); the translatability of animal models to the human clinical environment, the fact that different products present unique issues, and the challenge of evaluating innovative products when human clinical data are difficult to obtain.

FDA is organizing a hemostatic medical devices public workshop focused on the current challenges and opportunities with hemostatic medical devices for use in emergency situations. The participants include a broad range of stakeholders that are responsible for the design, testing, manufacturing, regulation, and use of hemostatic devices. Specifically, the public workshop is intended to foster open constructive dialogue:

  • On the challenges related to the design, development, evaluation, and use of hemostatic medical devices.
  • To facilitate collaboration amongst stakeholders interested in hemostatic medical device development and use.
  • To promote development of regulatory science tools for evaluating hemostatic medical devices.

II. Topics for Discussion at the Public Workshop

Topics to be discussed at the public workshop include, but are not limited to, the following:Start Printed Page 27877

1. The current landscape of products used for emergency treatment of bleeding and the respective Centers, Divisions, and Branches within FDA involved in their review.

2. Definitions of bleeding severity and methods for validating bleeding severity scales used in the evaluation of hemostatic devices.

3. Pre-clinical studies, including animal studies, that can be used to collect data when clinical data are difficult to obtain. What value do these models provide (for the evaluation of hemostatic medical devices?) and what are their shortcomings?

4. What options exist for obtaining clinical data for products used for emergency treatment of bleeding in both Civilian and Military settings, and which devices should be supported by clinical data?

5. Products used for emergency treatment of bleeding are often used by a variety of end users and in a variety of high-stress situations; improper or unnecessary device use has the potential to cause serious harm. What human factors issues exist with use of these products and how should these issues be studied?

6. Discussion of protocols used to study the topics, such as validation of bleeding severity, bench-top, animal, and human studies, and assessment of hemostatic devices used for non-compressible hemorrhage.

These topics will be presented by experts in the associated area, followed by more indepth discussions of the given topics in smaller breakout sessions.

Start Signature

Dated: May 9, 2014.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2014-11170 Filed 5-14-14; 8:45 am]